U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07557615) titled 'hCG Treatment for Rehabilitation From a TBI' on April 22.
Brief Summary: The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; Ovidrel(R)) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.
Study Start Date: Oct. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Traumatic Brain Injur...